Ethnic differences in drug metabolism and toxicity from chemotherapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 3, 2009, Pages 243-257

  Phan, Viet Hong ^a   Moore, Melissa M ^a   McLachlan, Andrew J ^a   Piquette Miller, Micheline ^b,c   Xu, Hongmei ^a   Clarke, Stephen J ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapy; Drug metabolism; Ethnic differences; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A1; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; GEFITINIB; IFOSFAMIDE; IMATINIB; IRINOTECAN; MERCAPTOPURINE; PACLITAXEL; TAMOXIFEN; TEGAFUR; THALIDOMIDE; TIOGUANINE; UNINDEXED DRUG; VINCRISTINE; CYTOCHROME P450;

ALLELE; ASIAN; BREAST CANCER; CAUCASIAN; CLINICAL TRIAL; DIETARY INTAKE; DRUG METABOLISM; DRUG TOLERABILITY; ETHNIC DIFFERENCE; ETHNICITY; FEBRILE NEUTROPENIA; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; INFLAMMATION; LUNG CANCER; LUNG SMALL CELL CANCER; NEGRO; NEUTROPENIA; PHARMACOGENOMICS; REVIEW; ANIMAL; ETHNOLOGY; GENETICS; METABOLISM; NEOPLASM; PHARMACOGENETICS;

ALLELES; ANIMALS; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; NEOPLASMS; PHARMACOGENETICS;

EID: 65549147273     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902800153     Document Type: Review

References (104)

1. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352(21):2211-2221
2. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348(6):538-549 (Pubitemid 36159890)
3. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84(3):417-423
4. Cropp CD, Yee SW, Giacomini KM. Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther 2008;84(3):412-416
5. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008;84(3):347-361
6. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008;105(5):1733- 1738 (Pubitemid 351346583)
7. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006;45(10):957-964 (Pubitemid 44436000)
8. Ma B, Yeo W, Hui P, et al. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002;62(2):185-189 (Pubitemid 34286451)
9. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health 2004;58(6):441-445
10. Ng PC, Zhao Q, Levy S, et al. Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther 2008;84(3):306-309
11. Suarez-Kurtz G. The implications of population admixture in race-based drug prescription. Clin Pharmacol Ther 2008;83(3):399-400; author reply (Pubitemid 351272632)
12. Available from: http://www.fda.gov/cber/gdlns/racethclin.pdf
13. Available from: www.imm.ki.se/CYPalleles
14. Robert J, Morvan VL, Smith D, et al. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005;54(3):171-196 (Pubitemid 40693684)
15. Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005;37(2):327-378 (Pubitemid 40677508)
16. Inoue K, Asao T, Shimada T. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 2000;30(3):285-295 (Pubitemid 30179142)
17. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19(8):1329-1332 (Pubitemid 28409826)
18. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2(1):93-109 (Pubitemid 46729082)
19. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45(3):253-285 (Pubitemid 43327492)
20. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11(7):597-607 (Pubitemid 32953585)
21. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
22. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999;13(6):289-295 (Pubitemid 129705404)
23. Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64(11):1579-1589 (Pubitemid 35333419)
24. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45(6):525-538 (Pubitemid 28270907)
25. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41(12):913-958 (Pubitemid 35168437)
26. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38(4):402-408 (Pubitemid 16250313)
27. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985;19(4):483-487 (Pubitemid 16254589)
28. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51(4):388-397
29. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52(2):160-169
30. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6(6):547-551 (Pubitemid 27032307)
31. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52(4):349-355 (Pubitemid 32939439)
32. Scordo MG, Caputi AP, D'Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50(2):195-200
33. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59(4):303-312 (Pubitemid 37100349)
34. Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit 2007;29(4):455-459 (Pubitemid 47220464)
35. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006;11(2):126-135 (Pubitemid 43261759)
36. Thompson EE, Kuttab-Boulos H, Yang L, et al. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006;6(2):105-114
37. Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005;353(1-2):187-192 (Pubitemid 40215445)
38. Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005;33(7):884-887 (Pubitemid 41002766)
39. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45(1):13-31 (Pubitemid 43145013)
40. Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998;51(3):391-400 (Pubitemid 28413205)
41. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40(7):939-950 (Pubitemid 38496249)
42. Hsiao HH, Yang MY, Chang JG, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 2004;53(5):445-451 (Pubitemid 38553668)
43. Maekawa K, Saeki M, Saito Y, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 2007;52(10):804-819 (Pubitemid 47512857)
44. Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008;76(3):404-415
45. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9(1):37-42 (Pubitemid 29176722)
46. Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J 2001;1(4):254-261 (Pubitemid 33756650)
47. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88 (Pubitemid 40261798)
48. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6(9):733-743 (Pubitemid 27427630)
49. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25(11):1639-1648
50. Zhong SL, Zhou SF, Chen X, et al. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 2006;28(1-2):77-85
51. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995;16(5):1243-1245
52. Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-580
53. Kuhne A, Sezer O, Heider U, et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 2008;83(5):749-757 (Pubitemid 351556013)
54. Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000;38(9):889-892 (Pubitemid 30814771)
55. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;95(14):8170-8174
56. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000;10(8):679-685
57. Jakobsson J, Ekstrom L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006;91(2):687-693 (Pubitemid 43236944)
58. Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17(8):647-656 (Pubitemid 47057714)
59. Chen CC, Lu RB, Chen YC, et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999;65(3):795-807 (Pubitemid 30468726)
60. Maring JG, Groen HJ, Wachters FM, et al. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5(4):226-243 (Pubitemid 41131715)
61. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000;61(3):199-203
62. Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81(1):76-82 (Pubitemid 46050869)
63. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237-2246 (Pubitemid 46621858)
64. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290(16):2149-2158 (Pubitemid 37432975)
65. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1(8):847-855 (Pubitemid 47181391)
66. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-1537 (Pubitemid 41540110)
67. Tamura T, Nishiwaki Y, Watanabe K, et al. Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies. J Thorac Oncol 2007;2(Suppl 4):S742
68. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-132 (Pubitemid 41058344)
69. Mok TSZC, Kim S, Wu Y, Perng R. Efficacy and safety of erlotinib in >1200 East/South-East (E/SE) Asian patients (pts) with advanced non-small-cell lung cancer (NSCLC) [abstract 19001]. J Clin Oncol 2008;26(15s):19001
70. Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 2006;53(2):157-164 (Pubitemid 43994238)
71. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008;60 (Suppl 2):S23-30
72. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24(14):2158-2163 (Pubitemid 46630688)
73. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-595 (Pubitemid 350002967)
74. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99(11):1757-1762
75. Lara PRM, Lenz H, Gordon M, et al. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. J Clin Oncol 2007;25(Suppl):390s
76. Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14(3):449-454 (Pubitemid 36367424)
77. Beith JMGB, Yeo W, Sullivan A, et al. Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proc Am Soc Clin Oncol 2002;21:252
78. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;33(2):103-121 (Pubitemid 27336951)
79. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69(1):14-23 (Pubitemid 32109323)
80. Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70(5):462-467 (Pubitemid 33135326)
81. Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999;117(1):89-98
82. Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979;25(1):88-95 (Pubitemid 9214959)
83. de la Maza MP, Hirsch S, Petermann M, et al. Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000;24(5):605-610 (Pubitemid 30337755)
84. Stein CM, Sadeque AJ, Murray JJ, et al. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001;69(5):317-323 (Pubitemid 32477072)
85. Ding X, Lichti K, Kim I, et al. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Biol Chem 2006;281(36):26540-26551 (Pubitemid 44401863)
86. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40(1):51-58
87. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4(4):224-232 (Pubitemid 36503320)
88. Robertson GR, Liddle C, Clarke SJ. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008;83(6):894-897 (Pubitemid 351704929)
89. Miller MA, Cappuccio FP. Ethnicity and inflammatory pathways- implications for vascular disease, vascular risk and therapeutic intervention. Curr Med Chem 2007;14(13):1409-1425 (Pubitemid 46902223)
90. Kalra L, Rambaran C, Chowienczyk P, et al. Ethnic differences in arterial responses and inflammatory markers in Afro-Caribbean and Caucasian subjects. [see comment]. Arterioscler Thromb Vasc Biol 2005;25(11):2362-2367
91. Mwantembe O, Gaillard MC, Barkhuizen M, et al. Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease (IBD) and in control individuals. Immunogenetics 2001;52(3-4):249-254 (Pubitemid 32142812)
92. Szalai AJ, Wu J, Lange EM, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level.[see comment]. J Mol Med 2005;83(6):440-447 (Pubitemid 40922166)
93. Lakoski SG, Cushman M, Palmas W, et al. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005;46(10):1869-1874 (Pubitemid 41579810)
94. Yamada H, Dahl ML, Lannfelt L, et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998;54(6):479-481 (Pubitemid 28418816)
95. Liou YH, Lin CT, Wu YJ, Wu LS. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J Hum Genet 2006;51(10):857-863 (Pubitemid 44465695)
96. Tamminga WJ, Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001;57(10):717-722 (Pubitemid 34031264)
97. Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2008 (E-pub ahead of time)
98. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90(1):8-11 (Pubitemid 38174930)
99. Reigner B, Watanabe T, Schuller J, et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003;52(3):193-201 (Pubitemid 37204532)
100. Shirao K, Matsumura Y, Yamada Y, et al. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Jpn J Clin Oncol 2006;36(5):295-300 (Pubitemid 43997334)
101. Ogawa M, Sampi K, Tsukui T, et al. Pharmacokinetic study of mitoxantrone. Gan To Kagaku Ryoho 1986;13(10):3028-3033 (Pubitemid 17214943)
102. Dowsett M, Donaldson K, Tsuboi M, et al. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother Pharmacol 2000;46(1):35-39 (Pubitemid 30432172)
103. Fukushima T, Yamashita T, Goto N, et al. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. Int J Hematol 2001;74(3):297-302 (Pubitemid 33760086)
104. Comets E, Ikeda K, Hoff P, et al. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn 2003;30(4):257-283 (Pubitemid 37352523)